
I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.
Education and Training
- Fellowship, Hematology Oncology, Duke University School of Medicine, 2011 - 2014
- Residency, Osler Medical Housestaff Training Program, Johns Hopkins University School of Medicine, 2008 - 2011
- M.D., Harvard University , 2008
Grants
- Statistical modeling of cross-sample variation and learning of latent structures in microbiome sequencing data
- A Randomized Phase 2 Trial to Evaluate Prebiotic Intervention in Allogeneic Hematopoietic Stem Cell Transplantation
- Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs
- Using a SMART Design to Optimize PTSD Symptom Management Strategies Among Cancer Survivors
- A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100days to 200 days post-transplant in cytomegalovirus (CMV) seropositive recipients (R+)
- Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilmumab in Subjects with Previously Untreated, Advanced or Metastatic RCC
- Hematopoietic Stem Cell Transplantation Combined with CSF1 Inhibition to Attenuate the Pathogenesis of Alzheimer's Disease
- Mitigators of Radiation-Induced Endovascular Injury: Targeting Tie2 and Thrombocytopenia
- Development and Pilot Testing of a Hybrid In Person and mHealth Coping Skills Training Intervention for Symptom Management and Daily Steps in Stem Cell Transplant Patients
- Personalized Prebiotics to Optimize Microbiota Metabolism and Improve Transplant Outcomes
- Home Transplant to Preserve the Microbiota and Decrease GVHD
- Keratinocyte targeted strategies for treatment of cutaneous GVHD
- Evaluating Effects of Age-related Microbiota Modulations in Hematopoietic Stem Cell Transplant Patients
- Patient-centered home-based hematopoietic stem cell transplantation